Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis

  1. Satish K Nandakumar
  2. Sean K McFarland
  3. Laura Marlene Mateyka
  4. Caleb A Lareau
  5. Jacob C Ulirsch
  6. Leif S Ludwig
  7. Gaurav Agarwal
  8. Jesse M Engreitz
  9. Bartlomiej Przychodzen
  10. Marie McConkey
  11. Glenn S Cowley
  12. John G Doench
  13. Jaroslaw P Maciejewski
  14. Benjamin L Ebert
  15. David E Root
  16. Vijay G Sankaran  Is a corresponding author
  1. Boston Children's Hospital, United States
  2. Broad Institute of MIT and Harvard, United States
  3. Cleveland Clinic, United States
  4. Brigham and Women's Hospital, United States
  5. Broad Institute of Harvard and MIT, United States

Abstract

Genome-wide association studies (GWAS) have identified thousands of variants associated with human diseases and traits. However, the majority of GWAS-implicated variants are in non-coding regions of the genome and require in depth follow-up to identify target genes and decipher biological mechanisms. Here, rather than focusing on causal variants, we have undertaken a pooled loss-of-function screen in primary hematopoietic cells to interrogate 389 candidate genes contained in 75 loci associated with red blood cell traits. Using this approach, we identify 77 genes at 38 GWAS loci, with most loci harboring 1-2 candidate genes. Importantly, the hit set was strongly enriched for genes validated through orthogonal genetic approaches. Genes identified by this approach are enriched in specific and relevant biological pathways, allowing regulators of human erythropoiesis and modifiers of blood diseases to be defined. More generally, this functional screen provides a paradigm for gene-centric follow up of GWAS for a variety of human diseases and traits.

Data availability

1000 Genomes human variation datasetThe 1000 Genomes Project Consortium. (2015)Recombinant hotspots access at:ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/technical/reference/Phase 1 data (for PLINK) accessed at: https://www.cog-genomics.org/plink/1.9/resourcesPhase 3 data accessed at: http://www.internationalgenome.org/category/phase-3/Pooled screen abundance data for shRNA targeting red blood cell trait GWAS-nominated genes during the course of in vitro differentiation of human CD34+ cellsSK Nandakumar, SK McFarland, et al. (2019)Available on the project's companion GitHub repository: https://github.com/sankaranlab/shRNA_screen/tree/master/ref/shref.csvEffects of shRNA knockdown of SF3A2 on splicing during human erythropoiesisSK Nandakumar, SK McFarland, et al. (2019)ID GSE129603. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/Effects of SF3B1 mutants on splicing in human erythropoiesisEA Obeng et al. (2016)ID GSE85712. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/SNP sets identified by GWAS of LDL, HDL, and triglyceride traitsCJ Willer et al. (2013)Accessed at: http://csg.sph.umich.edu/willer/public/lipids2013/Human hematopoietic lineage gene expressionMR Corces et al. (2016)ID GSE74912. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/Human adult and fetal erythropoiesis gene expressionH Yan et al. (2018)ID GSE107218. In the public domain at GEO https://www.ncbi.nlm.nih.gov/geo/

Article and author information

Author details

  1. Satish K Nandakumar

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Sean K McFarland

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Laura Marlene Mateyka

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Caleb A Lareau

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4179-4807
  5. Jacob C Ulirsch

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Leif S Ludwig

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Gaurav Agarwal

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Jesse M Engreitz

    Broad Institute of MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5754-1719
  9. Bartlomiej Przychodzen

    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Marie McConkey

    Division of Hematology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Glenn S Cowley

    Broad Institute of MIT and Harvard, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. John G Doench

    Broad Institute of MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3707-9889
  13. Jaroslaw P Maciejewski

    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Benjamin L Ebert

    Division of Hematology, Brigham and Women's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. David E Root

    Broad Institute of Harvard and MIT, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Vijay G Sankaran

    Division of Hematology/Oncology, Boston Children's Hospital, Boston, United States
    For correspondence
    sankaran@broadinstitute.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0044-443X

Funding

National Institutes of Health (R33HL120791)

  • Vijay G Sankaran

New York Stem Cell Foundation

  • Vijay G Sankaran

National Institutes of Health (R01DK103794)

  • Vijay G Sankaran

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: No human subjects were involved in the study. Human CD34+ HSPCs used in these experiments are deidentified and obtained from external sources. All mouse experiments were performed in full compliance with the approved Institutional Animal Care and Use Committee (IACUC) protocols at Boston Children's Hospital (Protocol # 18-05-3680R) and Brigham and Women's Hospital (Protocol # 2017N000060). These studies were approved by local regulatory committees in accordance with the highest ethical standards for biomedical research involving vertebrate animals.

Copyright

© 2019, Nandakumar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,892
    views
  • 436
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Satish K Nandakumar
  2. Sean K McFarland
  3. Laura Marlene Mateyka
  4. Caleb A Lareau
  5. Jacob C Ulirsch
  6. Leif S Ludwig
  7. Gaurav Agarwal
  8. Jesse M Engreitz
  9. Bartlomiej Przychodzen
  10. Marie McConkey
  11. Glenn S Cowley
  12. John G Doench
  13. Jaroslaw P Maciejewski
  14. Benjamin L Ebert
  15. David E Root
  16. Vijay G Sankaran
(2019)
Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis
eLife 8:e44080.
https://doi.org/10.7554/eLife.44080

Share this article

https://doi.org/10.7554/eLife.44080

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics
    Hans Tobias Gustafsson, Lucas Ferguson ... Oliver J Rando
    Research Article

    Among the major classes of RNAs in the cell, tRNAs remain the most difficult to characterize via deep sequencing approaches, as tRNA structure and nucleotide modifications can each interfere with cDNA synthesis by commonly-used reverse transcriptases (RTs). Here, we benchmark a recently-developed RNA cloning protocol, termed Ordered Two-Template Relay (OTTR), to characterize intact tRNAs and tRNA fragments in budding yeast and in mouse tissues. We show that OTTR successfully captures both full-length tRNAs and tRNA fragments in budding yeast and in mouse reproductive tissues without any prior enzymatic treatment, and that tRNA cloning efficiency can be further enhanced via AlkB-mediated demethylation of modified nucleotides. As with other recent tRNA cloning protocols, we find that a subset of nucleotide modifications leave misincorporation signatures in OTTR datasets, enabling their detection without any additional protocol steps. Focusing on tRNA cleavage products, we compare OTTR with several standard small RNA-Seq protocols, finding that OTTR provides the most accurate picture of tRNA fragment levels by comparison to "ground truth" Northern blots. Applying this protocol to mature mouse spermatozoa, our data dramatically alter our understanding of the small RNA cargo of mature mammalian sperm, revealing a far more complex population of tRNA fragments - including both 5′ and 3′ tRNA halves derived from the majority of tRNAs – than previously appreciated. Taken together, our data confirm the superior performance of OTTR to commercial protocols in analysis of tRNA fragments, and force a reappraisal of potential epigenetic functions of the sperm small RNA payload.

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.